Erlotinib
It is a quinazolinamine that acts on Epidermal Growth Factor Receptor (EGFR).It is indicated for the treatment of Non-Small Cell Lung Cancer, Pancreatic Cancer and serval other types of cancer.
150mg for NSCLC and 100mg for pancreatic cancer daily taken epmty stomach one hour before or two hours after the ingestion of food.
Cigarette smoking has been reported to reduce the effect of Erlotinib and is contraindicated..
Pulmonary Toxicity, Renal Failure, Hepatotoxicity, G.I. Perforation, Bullous and Exofoliative skin disorders, Myocardial Infarction, Cerebro-vascular accidents, ocular disorders. Pregnancy Category D medication. Erlotinib can cause fetal harm when administered to pregnant women.
Rashes, Diarrhoea, Loss of appetite, Fatigue, Interstial pneumonitis, partial hair loss, inflammation of eyes and mouth, Breathing problems.
Serious adverse reactions have also been reported with CYP3A4 inhibitor drugs. Rifampicin, Proton Pump Inhibitors, H2 Receptor Antagonists.
